This webinar will discuss the background of helper plasmids, how they have been used in the past, regulatory considerations and their advantages. Hosted by Aldevron.
Success in gene and cell therapy has increased demand for plasmid DNA used to produce viral vectors, both in quantities for commercial products as well as the breadth of different vectors for the expanding number of programs in development.
Data and analysis gathered by Aldevron indicate that standardization and large-scale production of helper plasmids, those that are the same regardless of the specific viral vector produced, represents an opportunity to significantly reduce timeline, cost and risk.
The availability, cost, freedom to operate, and consistency of these plasmids will help address the growing demands of cell and gene therapy.
Join this webinar to discuss:
- An introduction to standardized plasmids and their large-scale production for gene therapy
- An overview of plasmids common to AAV and Lentiviral productions (pALD-X80 and pALD-Lenti)
- Technical and regulatory considerations of helper plasmids
- Scalability of plasmid production and how standardization supports consistency and efficiency of large-scale manufacturing
- Data showing that the scalability of fermentation for a typical plasmid at 30 L and 300 L
- The performance of lentiviral vectors produced with optimized plasmids
Date: Thursday 30th May 2019
Time: 4pm BST | 11am EST
Attend: register here
MODERATOR: James Brown, Ph.D.
Vice President of Corporate Development at Aldevron
Chief Scientific Officer at Oxford Genetics Ltd
Chief Technology Officer at Asklepios BioPharmaceutical Inc